{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2025-10-25T12:20:18.702881+00:00",
  "news": [
    {
      "title": "With questions surrounding its gastric cancer drug, Amgen fills in some gaps - statnews.com",
      "link": "https://news.google.com/rss/articles/CBMie0FVX3lxTE1zNDBYYlJHWGU3TktJb1dpeUI0MkUxZFBpQklTbW1YT3BWWGw4RjVNSm5BOFBZTUJDamRmNUg3bVJaOHhqV21QZXF0MzdBOU14V1JVZVhseWNaSTI4M2NGa0xkbUJLVHhvel9SWDhYd251Y3l3aFAzZkZndw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMie0FVX3lxTE1zNDBYYlJHWGU3TktJb1dpeUI0MkUxZFBpQklTbW1YT3BWWGw4RjVNSm5BOFBZTUJDamRmNUg3bVJaOHhqV21QZXF0MzdBOU14V1JVZVhseWNaSTI4M2NGa0xkbUJLVHhvel9SWDhYd251Y3l3aFAzZkZndw?oc=5\" target=\"_blank\">With questions surrounding its gastric cancer drug, Amgen fills in some gaps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">statnews.com</font>",
      "published": "2025-10-20T14:52:07+00:00",
      "source": "statnews.com"
    },
    {
      "title": "ESMO 2025 – bemarituzumab fails to convince | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline",
      "link": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPME91bWdtOGVBLW54MmFCaWJ5UEcxaDFycnZuZXJBMlhUUXZyUndFckw0OTR1VjhHajV1VHlWSlJaX3l3bWRTUS1PbGwtVjR3V0ZoaXRUYXMxV3dZbUdUa1E1TDhMWWRCRmcwNnlKVlpVRm9rYmRQNy1SY2hSa1diaThJXzVfS1E?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihwFBVV95cUxPME91bWdtOGVBLW54MmFCaWJ5UEcxaDFycnZuZXJBMlhUUXZyUndFckw0OTR1VjhHajV1VHlWSlJaX3l3bWRTUS1PbGwtVjR3V0ZoaXRUYXMxV3dZbUdUa1E1TDhMWWRCRmcwNnlKVlpVRm9rYmRQNy1SY2hSa1diaThJXzVfS1E?oc=5\" target=\"_blank\">ESMO 2025 – bemarituzumab fails to convince | ApexOnco - Clinical Trials news and analysis</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Oncology Pipeline</font>",
      "published": "2025-10-21T13:50:35+00:00",
      "source": "Oncology Pipeline"
    },
    {
      "title": "Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices - The New York Times",
      "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPOGtMT0RzU0RhVGtHcjRGc1ZveDNZOUJLMGh3eVB2S3Eyb21tSUpmczRHUEtmWUYtdnlXVGNFUHN6RUVNa3BtZGNGcG1zVEJaZEZUdi03R2R4VHVENzBxcjhrektwRTNFOWpOSTZuSzFpbkRWZktQeDROQkdiV0RCcnBpRFljTDRXSkhWbklkZFhNLW8?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMikwFBVV95cUxPOGtMT0RzU0RhVGtHcjRGc1ZveDNZOUJLMGh3eVB2S3Eyb21tSUpmczRHUEtmWUYtdnlXVGNFUHN6RUVNa3BtZGNGcG1zVEJaZEZUdi03R2R4VHVENzBxcjhrektwRTNFOWpOSTZuSzFpbkRWZktQeDROQkdiV0RCcnBpRFljTDRXSkhWbklkZFhNLW8?oc=5\" target=\"_blank\">Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">The New York Times</font>",
      "published": "2025-10-23T09:00:45+00:00",
      "source": "The New York Times"
    },
    {
      "title": "Top Research Reports for Amazon.com, Wells Fargo & Amgen - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPbndFZmNreDltZTBwNE5HRHFmWmFDQXJTVzZNQTZ1OXIwOG5sUDRXVlRGWS1Vd2VQRzZ3QlAycHVrcVhsWXd3UGItMlRRZ0RlcFhjdzFTaWJpdTF0bjQ1NF9kdENEUm1IUVNLTjRodkFxd2RJR1BsWm5CeXdES2JEeFkyaw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMigwFBVV95cUxPbndFZmNreDltZTBwNE5HRHFmWmFDQXJTVzZNQTZ1OXIwOG5sUDRXVlRGWS1Vd2VQRzZ3QlAycHVrcVhsWXd3UGItMlRRZ0RlcFhjdzFTaWJpdTF0bjQ1NF9kdENEUm1IUVNLTjRodkFxd2RJR1BsWm5CeXdES2JEeFkyaw?oc=5\" target=\"_blank\">Top Research Reports for Amazon.com, Wells Fargo & Amgen</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-23T20:41:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "Biogen Takes Aim At Amgen’s Tavneos With Vanqua Licensing Pact - Citeline News & Insights",
      "link": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxNR1U3c3FDRWp5c3R1RV9MdjBaVDBnNFNMM0JoNlNYWXp0N2lIZHFkMFpBN21qc3J4ZHpCdHF5UUJDcGpuZkVKcmRwd05JTmVUSVhjS1k2REtjUWtlaXZmY29yQllnRmdWZEZQZVZGUVNSa0llXzdJcmM4MkRtR3BHdVNyWlJ6STdjSjRuTmtVWE05aE9CU2NDb3pxTi1kY0tmZVlxQXZkZlR3LWY2UEJoMmxUaThMWEVqMnJmYnFfWXJRYmw3dlI5Q0FjSlJWUHplTkY2RFdvaw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNR1U3c3FDRWp5c3R1RV9MdjBaVDBnNFNMM0JoNlNYWXp0N2lIZHFkMFpBN21qc3J4ZHpCdHF5UUJDcGpuZkVKcmRwd05JTmVUSVhjS1k2REtjUWtlaXZmY29yQllnRmdWZEZQZVZGUVNSa0llXzdJcmM4MkRtR3BHdVNyWlJ6STdjSjRuTmtVWE05aE9CU2NDb3pxTi1kY0tmZVlxQXZkZlR3LWY2UEJoMmxUaThMWEVqMnJmYnFfWXJRYmw3dlI5Q0FjSlJWUHplTkY2RFdvaw?oc=5\" target=\"_blank\">Biogen Takes Aim At Amgen’s Tavneos With Vanqua Licensing Pact</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Citeline News & Insights</font>",
      "published": "2025-10-24T18:54:13+00:00",
      "source": "Citeline News & Insights"
    },
    {
      "title": "The Zacks Analyst Blog Highlights Amazon.com, Wells Fargo, Amgen, IDT and Village Super Market - Zacks Investment Research",
      "link": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOTnltbWNMOW01UG9SXzBhYnRMaXRpY0t4ZjlpZkRlUGp1SVE1WExla1pGVlRXMVRIUHByamJWNzh2SmFHMFNGM2s5M1NSdnlWQnJOeEVvSGl0V284VVR3NVpRdERPckdIZ0NsRXk2M1FDc1dVakRmVFcwaXBsNUhzNjdrTWx5OVpncGE1cHF5d2cwdFNUMG02WVdGY3BDV2RoWkZJdUZJQkNQc2gxN3J4djBsTGFrRlVVczVrWnVaY0V1Um5KV1NHV0FLYw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiywFBVV95cUxOTnltbWNMOW01UG9SXzBhYnRMaXRpY0t4ZjlpZkRlUGp1SVE1WExla1pGVlRXMVRIUHByamJWNzh2SmFHMFNGM2s5M1NSdnlWQnJOeEVvSGl0V284VVR3NVpRdERPckdIZ0NsRXk2M1FDc1dVakRmVFcwaXBsNUhzNjdrTWx5OVpncGE1cHF5d2cwdFNUMG02WVdGY3BDV2RoWkZJdUZJQkNQc2gxN3J4djBsTGFrRlVVczVrWnVaY0V1Um5KV1NHV0FLYw?oc=5\" target=\"_blank\">The Zacks Analyst Blog Highlights Amazon.com, Wells Fargo, Amgen, IDT and Village Super Market</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Zacks Investment Research</font>",
      "published": "2025-10-24T16:00:56+00:00",
      "source": "Zacks Investment Research"
    },
    {
      "title": "Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers - CNBC",
      "link": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPWkRpS1ROdl9hMEp5dl9hTm9HaEJBR1NEdFJXNmpVbHNjaUUyeExYdDRodVJkREl5Q3ItdWM1aTQyby1tb0VrQjIxUmpFMEx3Z3RoaTkwTkNIcTQ1QU5LVXNHbmtfYWQyWjZ2VEFpNlBYdmJsVk16R0tDY3lKR2lmTl94V0NBVGF4ejdzZ2ZPbVdDVzNWaldyMXhoY9IBoAFBVV95cUxQUnozRC1oUHNMRUt5NnRpUl9xLXplTC10bjVpYmJucHd4WGRUZEVSRUQ0UG5BZnEteWNjNEVJR3R5VnpHRUJycVZGamZFV2wtNnM2UTFKSGt3dk5ROGNpeklQN2U4LTBYNUVyYl9SZzZTSFcyMWluaFdHZWszRjJiYzZqOUVSbWVxNTRRLU5lay1uNmJPNU1BSXZ0dDJzVEhI?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWkRpS1ROdl9hMEp5dl9hTm9HaEJBR1NEdFJXNmpVbHNjaUUyeExYdDRodVJkREl5Q3ItdWM1aTQyby1tb0VrQjIxUmpFMEx3Z3RoaTkwTkNIcTQ1QU5LVXNHbmtfYWQyWjZ2VEFpNlBYdmJsVk16R0tDY3lKR2lmTl94V0NBVGF4ejdzZ2ZPbVdDVzNWaldyMXhoY9IBoAFBVV95cUxQUnozRC1oUHNMRUt5NnRpUl9xLXplTC10bjVpYmJucHd4WGRUZEVSRUQ0UG5BZnEteWNjNEVJR3R5VnpHRUJycVZGamZFV2wtNnM2UTFKSGt3dk5ROGNpeklQN2U4LTBYNUVyYl9SZzZTSFcyMWluaFdHZWszRjJiYzZqOUVSbWVxNTRRLU5lay1uNmJPNU1BSXZ0dDJzVEhI?oc=5\" target=\"_blank\">Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">CNBC</font>",
      "published": "2025-10-07T07:00:00+00:00",
      "source": "CNBC"
    },
    {
      "title": "AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS - PR Newswire",
      "link": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVC03UXRKQ3Q4OTFzYjh5bUV6WWRRRHVOU2pqcDY1MGhUbm1PQnZCTEpQYzZhcFlsN2pDSHZTU0xib0JuVVhuTlBMMVVuRGhtX1F0clBxVHM2Z2lUR1VRSkItM3VvVGh6R0NPMWhaTkRZRGVOVlFhNzdGUkZ5UWpzRk4zU2xIdkdRMkFrRl83UjB2LXFjMWdRUXh1aUs3WG94SXI5NWJqVVEyYzFSZVY5TERfZGlJOC1DbVM4RnNBbFJOVW9GbW9PQ1NydXBsdHdtTkE?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi0gFBVV95cUxOVC03UXRKQ3Q4OTFzYjh5bUV6WWRRRHVOU2pqcDY1MGhUbm1PQnZCTEpQYzZhcFlsN2pDSHZTU0xib0JuVVhuTlBMMVVuRGhtX1F0clBxVHM2Z2lUR1VRSkItM3VvVGh6R0NPMWhaTkRZRGVOVlFhNzdGUkZ5UWpzRk4zU2xIdkdRMkFrRl83UjB2LXFjMWdRUXh1aUs3WG94SXI5NWJqVVEyYzFSZVY5TERfZGlJOC1DbVM4RnNBbFJOVW9GbW9PQ1NydXBsdHdtTkE?oc=5\" target=\"_blank\">AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">PR Newswire</font>",
      "published": "2025-09-26T07:00:00+00:00",
      "source": "PR Newswire"
    }
  ],
  "product_launches": [
    {
      "title": "Forecast Cut: Will Amgen Inc. (AMG0) stock deliver stable dividends - Product Launch & Low Risk Entry Point Tips - nchmf.gov.vn",
      "link": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQbEg2SXdxLU80YmdHQnVEQ0VMYl9hYlRieVJmVEpSbWFUYkpKMl9BQy1ISE14S29RT095dVlvaUlJVzdqVHVpdG5MVG5UdS1iTTFYemluX3FxNTh1OFk2Z3NjVjZfa3BCX29MQUN6UGR3NTZfMGNjWEZLX21jN3NNbGI5NGRDRXpLZW40RENsZVgyUjg?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMikwFBVV95cUxQbEg2SXdxLU80YmdHQnVEQ0VMYl9hYlRieVJmVEpSbWFUYkpKMl9BQy1ISE14S29RT095dVlvaUlJVzdqVHVpdG5MVG5UdS1iTTFYemluX3FxNTh1OFk2Z3NjVjZfa3BCX29MQUN6UGR3NTZfMGNjWEZLX21jN3NNbGI5NGRDRXpLZW40RENsZVgyUjg?oc=5\" target=\"_blank\">Forecast Cut: Will Amgen Inc. (AMG0) stock deliver stable dividends - Product Launch & Low Risk Entry Point Tips</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">nchmf.gov.vn</font>",
      "published": "2025-10-18T06:18:36+00:00",
      "source": "nchmf.gov.vn"
    },
    {
      "title": "Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5\" target=\"_blank\">Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2025-09-10T07:00:00+00:00",
      "source": "BioSpace"
    },
    {
      "title": "$239/month for Repatha — AmgenNow direct-to-patient program offers nearly 60% discount in U.S. - Stock Titan",
      "link": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNX1VmYlB3RmtYTG5rd1dJblFhNVh6UEFHdzkxTm9VRy0wMVc1SDNuZ0JLYUNRTHA0VVhBOEpWb1RUa2FONTVMY19CSTJSVVJSUjFwbkIwMFdtalFEWHRmQTVvQnFzY3YxYUFqaDc2cjBydnV0RjdSWGhCTzdaWDl1Y2VNVU9LdzZvLW1FZHhnam12Qm1XaEg0M3ZEeTh4aHNkcUZsazNRa0tuTGY3WXNiZjZKSnh2SkJRVVl6OXRR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivgFBVV95cUxNX1VmYlB3RmtYTG5rd1dJblFhNVh6UEFHdzkxTm9VRy0wMVc1SDNuZ0JLYUNRTHA0VVhBOEpWb1RUa2FONTVMY19CSTJSVVJSUjFwbkIwMFdtalFEWHRmQTVvQnFzY3YxYUFqaDc2cjBydnV0RjdSWGhCTzdaWDl1Y2VNVU9LdzZvLW1FZHhnam12Qm1XaEg0M3ZEeTh4aHNkcUZsazNRa0tuTGY3WXNiZjZKSnh2SkJRVVl6OXRR?oc=5\" target=\"_blank\">$239/month for Repatha — AmgenNow direct-to-patient program offers nearly 60% discount in U.S.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Stock Titan</font>",
      "published": "2025-10-06T07:00:00+00:00",
      "source": "Stock Titan"
    },
    {
      "title": "Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxONkt3YUVEeUpwTU5LYVgtaTk2THhoMEt3ZUliWC1sWmhTTGR4M0hwaVpFMEFla01mUTdxbGVueWNGVThVT3U1T3R2NTQwaEkxeEI5MjRPMzVQUlhaU3hKNVVqQmFFY3BMQ2c3enphdTVLVy1Wb3dTb0l4Rnk3czFVTVFZbUdvVVJwa1I4Z3FDOFByVDZIV21Ccnk5VTd5U3VtNHhuVDdQUldHNm81YnZ6MHFReDBJNmk1S3BucTJhUlplcnc?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiwwFBVV95cUxONkt3YUVEeUpwTU5LYVgtaTk2THhoMEt3ZUliWC1sWmhTTGR4M0hwaVpFMEFla01mUTdxbGVueWNGVThVT3U1T3R2NTQwaEkxeEI5MjRPMzVQUlhaU3hKNVVqQmFFY3BMQ2c3enphdTVLVy1Wb3dTb0l4Rnk3czFVTVFZbUdvVVJwa1I4Z3FDOFByVDZIV21Ccnk5VTd5U3VtNHhuVDdQUldHNm81YnZ6MHFReDBJNmk1S3BucTJhUlplcnc?oc=5\" target=\"_blank\">Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2025-01-28T08:00:00+00:00",
      "source": "Fierce Pharma"
    },
    {
      "title": "Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns - Seeking Alpha",
      "link": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNldFcDdyVUNrRFhsN2JMUDZuakRJNDN5R0JBNzFfbXNuaGVLVTRubVhsV3l2eEk4MGR2X2xLcXVON3NHVVZOVjZvZHNzdHBsTGVNZEFJaEp2WGRxUnNYdng4TS1yaWNrd1g5bW5tcnNvZUh1QzlleW96akRZUG1tNGRKLXdqdmg5TUdudlpielVzcHd2VUpYa3pfWkJjX0lESEJDc3BET1hFWGtreWdqNEdkNlMtT2dncThfMVVuOA?oc=5\" target=\"_blank\">Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Seeking Alpha</font>",
      "published": "2025-07-15T07:00:00+00:00",
      "source": "Seeking Alpha"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2025-10-24",
      "close": 291.760009765625
    },
    "history": [
      {
        "date": "2025-10-16",
        "close": 295.80999755859375
      },
      {
        "date": "2025-10-17",
        "close": 298.80999755859375
      },
      {
        "date": "2025-10-20",
        "close": 303.3299865722656
      },
      {
        "date": "2025-10-21",
        "close": 301.1400146484375
      },
      {
        "date": "2025-10-22",
        "close": 295.9800109863281
      },
      {
        "date": "2025-10-23",
        "close": 292.8900146484375
      },
      {
        "date": "2025-10-24",
        "close": 291.760009765625
      }
    ],
    "name": "Amgen Inc."
  }
}